Background: Antibiotic use may contribute to the rates of bacteremia, sepsis and associated
Introduction
Rates of hospitalization with septicemia and sepsis in the diagnosis, associated mortality, as well as monetary costs of those hospitalizations have been rising rapidly during the past decades in the US [1] [2] [3] [4] . A recent estimate from the US CDC suggests that about 270,000 Americans die annually as a result of sepsis [5] . Moreover, that estimate is expected to increase significantly if longer-term, e.g. 90-day mortality following sepsis diagnosis is accounted for [6] . In England, while rates of certain severe infections and related mortality, such as Clostridium difficile infections and MRSA bacteremia have declined during recent years [7, 8] , rates of E. coli and MSSA bacteremia and associated mortality were increasing [7] [8] [9] .
Bacteremia outcomes in England are laboratory confirmed and there is less uncertainty about the interpretation of the recorded trends for those outcomes compared to trends for septicemia/sepsis hospitalization rates in the US. Part of the reason behind the rapid growth in the rates of hospitalization with septicemia/sepsis in the diagnosis in the US is changes in diagnostic practices, including the implementation of sepsis screening protocols [10, 11] . However, changes in diagnostic practices in the US cannot fully explain the rise in the rates of hospitalization with septicemia/sepsis in the diagnosis, particularly prior to 2010 [12] . Indeed, trends in the rates of hospitalizations with Antibiotic use and resistance can contribute to the rates of bacteremia/sepsis hospitalization and mortality through several mechanisms, particularly lack of clearance of resistant infections/colonization following antibiotic treatment, with some of those infections subsequently devolving into bacteremia/sepsis, and lethal outcomes [13] [14] [15] [16] [17] [18] [19] . Some of the more direct evidence for the relation between antibiotic resistance and subsequent hospitalization with severe infections, including bacteremia/sepsis is described in [19, 18] ; evidence about the relation between antibiotic resistance for hospitalized patients with sepsis and mortality, particularly in the US is presented in [16, 17] . Antibiotic use is an important driver of the prevalence of antibiotic resistance [20] [21] [22] [23] 9] , and as such, it further contributes to the rates of sepsis and associated mortality. Moreover, antibiotic use may also contribute to the prevalence of resistance not only to the drug class used, but to other drugs as well as resistance to different drug classes tends to cluster in bacterial populations, leading to the phenomenon of co-selection [24, 25] . For example, fluoroquinolone use was found to be associated with methicillin-resistant S. aureus (MRSA) infections [26] [27] [28] , while amoxicillin use was found to be associated with trimethoprim resistance in Enterobacteriaceae in England [20] , with trimethoprim resistance in urinary tract infections (UTIs) being positively associated with bacteremia outcomes [21] . Furthermore, prevalence of co-amoxiclav resistance in E. coli bacteremia in England is very high [29] , and use of co-amoxiclav [30] and possibly related penicillins may contribute to the incidence of co-amoxiclav-resistant E. coli infections/colonization and associated bacteremia outcomes.
Our earlier work [13, 14] has shown associations between the use of different antibiotics and rates of septicemia hospitalization and mortality in the US, including the association between the use of penicillins and rates of septicemia hospitalization and mortality in older adults. We also note that prevalence of resistance to penicillins, particularly in older US adults, is high for a variety of infections with both Gram-negative and Gram-positive bacteria [31] [32] [33] . Additionally, rates of overall antibiotic prescribing are strongly correlated with rates of septicemia mortality in US adults, and rates of bacteremia in England (e.g. Tables 1 and 5 in this paper), with some of the geographic variability in antibiotic prescribing rates, at least in England, being associated with variability in the prevalence of underlying health conditions and certain demographic factors [34] . However, less is known about the effect of using some antibiotics vs. others in the treatment of various syndromes on the rates of bacteremia, septicemia, and associated mortality. In this paper, we examine how the proportions of overall antibiotic prescribing that are for different antibiotic types/classes are related to the rates of E. coli and MSSA bacteremia in England, and the rates mortality with septicemia in different age groups of US adults. Those analyses are based on state-level US CDC data on antibiotic prescribing and mortality between 2014-2015 in [35, 36] , and on the Clinical Commissioning Groups (CCG)-level English data (from Oxford U/PHE) on antibiotic prescribing and bacteremia [37, 38] . Additionally, we use a multivariable framework to relate the proportions of overall antibiotic prescribing that are for fluoroquinolones, penicillins, cephalosporins and macrolides to rates of mortality with septicemia in different age groups of US adults, adjusting for additional covariates and random effects. We hope that such ecological analyses would lead to further work on the effect of antibiotic prescribing, including the effect of replacing some antibiotics by others, as well as of reduction in antibiotic prescribing on the rates of bacteremia, sepsis and associated mortality.
Methods

Data
US.
Data on annual state-specific mortality with septicemia (ICD-10 codes A40-A41.xx representing either the underlying or a contributing cause of death) between 2014-2015 for different age groups of adults (18-49y, 50-64y, 65-74y, 75-84y, 85+y) were extracted from the US CDC Wonder database [36] . We note that for most of those deaths, septicemia is listed as a contributing rather than the underlying cause of death on the death certificate [39] . Data on the annual state-specific per capita rates of outpatient prescribing for four classes of antibiotics: fluoroquinolones, penicillins, macrolides, and cephalosporins, as well as overall antibiotic prescribing in different states in 2014 and 2015 were obtained from the US CDC Antibiotic Patient Safety Atlas database [35] . Annual state-specific population estimates in each age group of adults (overall, as well as the number of African-Americans) were obtained as the yearly July 1 population estimates in [40] . Data on median household income for US states between 2014-2015 were extracted from [41] . Data on average daily temperature for US states were obtained from [42] . Data on the percent of state residents in different age groups who lacked health insurance were extracted form the US Census Bureau database [43] . We've also extracted CCG/year specific data on the prescribing of all antibiotics per 1,000 residents, as well as per 1,000 STAR-PUs [37, 44] . In addition to prescribing data, we've extracted CCG/year-specific data on the (population-adjusted) rates of E. coli and MSSA bacteremia for each of the financial years 2014/15 through 2017/18 [38] .
Correlation analysis
The contribution of prescribing of a given antibiotic type/class to the rates of severe outcomes associated with bacterial infections (e.g. bacteremia, or mortality with septicemia) is expected to be proportional to the rate of prescribing of that antibiotic type/class. One of the factors that modulates the relationship between the rates of antibiotic prescribing and rate of severe outcomes is the rate of infection that affects both prescribing and severe outcomes. Correspondingly, associations between rates of antibiotic prescribing and rates of severe outcomes are often positive (e.g. Tables 1 and 5 in this paper). The effect of the proportion of given antibiotic type/class among all antibiotics prescribed on the rates of severe outcomes associated with bacterial infections is expected to be proportional to the rates of severe outcomes per unit of antibiotic prescribing, defined as the rates of severe outcomes divided by the rates of prescribing of all antibiotics. If a unit of prescribing of a given antibiotic type/class affects the rate of a given severe outcome disproportionately (e.g. as a result of high prevalence of resistance to a given antibiotic) compared to the affect of prescribing of an average antibiotic dose, the association between the proportion of given antibiotic type/class among all antibiotics prescribed and the rate of a given severe outcome per unit of antibiotic prescribing is expected to be positive. We note that such disproportionate effects of prescribing of a unit of a given antibiotic can be the result not only of treatment of infections leading to a given outcome by a given antibiotic, but also of the contribution of the use of a given antibiotic to the rates of infection/colonization with different bacteria, and the prevalence of resistance to other antimicrobials (see Introduction). Additionally, correlations between proportions of a given antibiotic type/class among all antibiotics prescribed and the rates of severe outcomes per unit of antibiotic prescribing can also be affected by patterns of antibiotic prescribing in different locations, including changes in those patterns resulting from increases in resistance, introduction of new prescribing guidelines, etc. Correspondingly, we studied correlations between the proportions (state-specific in the US, CCG-specific in England) of a given antibiotic type/class among all prescribed antibiotics in the outpatient setting, and rates of outcome (mortality with septicemia in 
Multivariable model (US data)
For each age group of adults, (18-49y, 50-64y, 65-74y, 75-84y, 85+y), we applied multivariable linear regression to relate the average annual state-specific outpatient prescribing rates (per 1,000 state residents) for fluoroquinolones, penicillins, macrolides, and cephalosporins between 2014-2015 to the average annual state-specific rates of septicemia mortality per 100,000 individuals in a given age group between 2014-2015 (dependent variable). Besides the antibiotic prescribing rates, the other covariates were the state-specific median household income, percentages of state residents in a given age group who were African American, those who lacked health insurance (in the non-elderly age groups, as health insurance, particularly Medicare coverage levels in the elderly are very high), as well as the state-specific average annual temperature. We note that septicemia mortality rates in African Americans are elevated [45] . We also note that temperature may influence bacterial growth rates and/or transmission mediated effects [46] , which in turn may affect both the prevalence of antibiotic resistance [46] , and the acquisition/severity of bacterial infections. To adjust for additional factors not accounted for by the covariates used in the model, we include random effects for the ten Health and Human Services (HHS) regions in the US. Specifically, for each state , let be the average annual state-specific rate of mortality (per 100,000) with septicemia in the given age group between 2014-2015, ! ( = 1, . . ,4) be the average annual state-specific outpatient prescribing rates, per 1,000 state residents, for the four studied classes of antibiotics between 2014-2015; be the median state-specific household income between 2014-2015; be the state-specific average annual temperature (℉) between 2002-2011; be the age-specific percent of state residents between 2014-2015 who were African American; be the average annual age-specific percent of state residents who lacked health insurance between 2014-2015 (for non-elderly age groups); and ( ) be the random effect for the corresponding HHS region. Then
We note that is we divide eq. 1 by the state-specific rates of overall outpatient antibiotic prescribing, the resulting equation expresses (models) a linear relation between septicemia mortality rates per unit of antibiotic prescribing, proportions of the overall antibiotic prescribing that are for fluoroquinolones, penicillins, macrolides, and cephalosporins, and other covariates. Thus, eq. 1 can be thought of as a re-examination of the correlation between proportion of overall antibiotic prescribing that is for a given antibiotic type/class and rate of outcome per unit of antibiotic prescribing defined in a previous subsection in a multivariable framework (Discussion). Table 2 with Table   6 ). Those differences, particularly for fluoroquinolones and cephalosporins may be related to differences in the rates of severe bacterial infections, particularly Clostridium difficile (C. diff)
Results
US
infections between the two countries [47] , with reduction in fluoroquinolone and cephalosporin prescribing found to be associated with reduction in the incidence of C. diff infection [48, 49] . annual state-specific percent of overall outpatient antibiotic prescribing that is for a given antibiotic class and average annual state-specific rates of mortality with septicemia in a given age group per unit of prescribed antibiotics (Methods) between 2014-2015. Table 4 shows the results of the multivariable model given by eq. 1. Table 4 suggests positive associations (with largest effect size in the corresponding age groups) between rates of prescribing of penicillins and septicemia mortality rates in individuals aged 75-84y and 85+y, and a negative association between rates of prescribing of penicillins and septicemia mortality rates in individuals aged 18-49y, all of which agree with the univariate results in Table 3 . Table 4 Table 5 shows annual rates of E. coli and MSSA bacteremia for the different CCGs (mean + standard error) for the 2014/15 through the 2017/18 financial years, as well as the correlation between those rates and the rates of antibiotic prescribing, both per 1,000 residents and per 1,000 STAR-PUs [44] . Table 5 suggests an ongoing increase in the rates of MSSA bacteremia [7] , with the long-term growth in the rates of E. coli bacteremia [38, 29, 50, 9] stalling in 2017/18. for the 2014/15 through the 2017/18 financial years; correlations between those bacteremia rates and rates of overall antibiotic prescribing, both per 1,000 residents and per 1,000 STAR-PUs [44] . Table 6 shows annual CCG-specific rates of prescribing of different antibiotic types/classes per 1,000 residents (mean + standard error), as well as the annual CCG-specific proportions of those antibiotic types/classes among all prescribed antibiotics (mean + standard error) for the 2014/15 through the 2017/18 financial years. Table 6 suggests significant temporal reduction in the rates/proportions of prescribing for trimethoprim, co-amoxiclav and cephalosporins/other beta lactams, as well as reduction in the rates/proportions of amoxicillin, fluroquinolone and macrolide prescribing. Prescribing of UTI antibiotics (BNF 5.1.13 --nitrofurantoin/fosfomycin/methenamine) increased markedly (with a good amount of replacement of trimethoprim by nitrofurantoin in the treatment of UTIs taking place during the study period, [29] ), with proportions of penicillins other than amoxicillin/co-amoxiclav and tetracyclines among all prescribed antibiotics also increasing.
England
Additionally, significant reduction in trimethoprim prescribing took place in 2017/2018 compared to 2016/17, and growth in the rate of E. coli bacteremia had stalled then (Tables 6 and 5 Tables 7 and 8 show correlations (both linear and Spearman) between CCG-specific proportions of different antibiotic types/classes among all prescribed antibiotics and rates of E. coli (Table 7) and MSSA (Table 8) 
Discussion
Rates of mortality related to septicemia/sepsis in the US, as well as rates of E. coli bacteremia and associated mortality in England are high [1] [2] [3] 5, 7, 8, 29] and antimicrobial use may affect those rates through a variety of mechanisms (Introduction). At the same time, our understanding of the effect of the use of certain antibiotics vs. others for various indications on the rates of bacteremia, septicemia and associated mortality is still limited. Additionally, use of certain antibiotics may affect the rates of severe outcomes associated with syndromes for which a given antibiotic is rarely prescribed as use of antibiotics may affect prevalence of infection/colonization and resistance to different antibiotics in different bacterial pathogens that subsequently cause various syndromes (Introduction). In this paper, we relate the proportions of different antibiotic types/classes among the overall volume of outpatient antibiotic prescription in different US states and English CCGs [35, 37] to rates of mortality with septicemia in different age groups of US adults [36] and rates of E. coli and MSSA bacteremia in England [38] . Our results suggest, among other things, that prescribing of penicillins is associated with rates of E. coli and MSSA bacteremia in England, and rates of mortality with septicemia in older US adults, with the latter finding supporting our earlier results on the association between the use of penicillins and rates of septicemia hospitalization and mortality in older US adults [13, 14] . Additionally, multivariable analysis of the US data suggest a positive association between the percent of individuals lacking health insurance and rates of mortality with septicemia in persons aged 50-64y, as well as the percent of individuals who are African-American and rates of mortality with septicemia in persons aged 65-84y, supporting the fact that rates of mortality with septicemia in African Americans are elevated [45] . More granular analyses are needed to better understand the effect of prescribing of different antibiotics, including the effect of antibiotic, particularly penicillin replacement, as well as of reduction in antibiotic prescribing on the rates of bacteremia, septicemia and associated mortality, as explained further in the next two paragraphs.
Our findings about the positive associations between the use of penicillins and mortality with septicemia in older US adults are in agreement with the fact that prevalence of resistance to penicillins, particularly in older adults, is high for a variety of infections with both Gram-negative and Gram-positive bacteria [31] [32] [33] . Negative associations between the proportion of cephalosporins among all antibiotic prescriptions and rates of septicemia mortality in older US adults (Table 3 ) may be related to the competition in prescribing with other antibiotic classes, particularly penicillins and fluoroquinolones for which prevalence of resistance in the key syndromes leading to sepsis is higher than prevalence of resistance to cephalosporins, e.g. [31, 51] .
We note that those negative associations do not reach significance in the multivariable model (Table   4 ). Moreover, prevalence of cephalosporin resistance and the frequency of extended-spectrum betalactamase (ESBL) production, including in Gram-negative bacteria is growing [52] , and replacement of other antibiotics by cephalosporins might potentially lead to negative effects in the long run.
Finally, we found no associations between the proportion of macrolides among all antibiotic prescriptions in the US and rates of mortality with septicemia in adults, which agrees with our earlier findings [13, 14] . While macrolides are used relatively infrequently in the treatment of urinary tract and gastrointestinal infections, macrolides are commonly prescribed in the treatment of other sources of sepsis, particularly respiratory illness, both chronic [53] and acute, including pneumonia [54] , with high prevalence of macrolide resistance in the corresponding infections [55] .
In England, prevalence of resistance to trimethoprim in urinary tract infections (UTIs) is high [50] , and trimethoprim use was found to be associated with UTI-related E. coli bacteremia [21] . Major reductions in trimethoprim prescribing in England took place in the recent years, particularly in 2017/2018 ( [29] ; Table 6 in this paper); moreover, prescribing of trimethoprim declined disproportionately in places in England with higher rates of E. coli and MSSA bacteremia (Results).
All those changes might have played a role in the fact that growth in the rates of E. coli bacteremia in England has stalled in 2017/2018 after many years of robust increases (Table 5 ; [38, 29, 50, 9] ).
Prevalence of co-amoxiclav resistance in E. coli bacteremia in England is very high [29] , and outpatient prescribing of co-amoxiclav was reduced significantly during the recent years ( [29] ; Table 6 in this paper), disproportionately in places with higher rates of bacteremia (Results). At the same time, prevalence of co-amoxiclav resistance in E. coli bacteremia and rates of the corresponding bacteremia outcomes are affected not only by GP prescribing of co-amoxiclav but also by other factors including clinic use of co-amoxiclav (inpatient/outpatient), and possibly the use of related penicillins. We note that amoxicillin use is also associated with trimethoprim resistance [20] , which in turn affects the rates of E. coli bacteremia [21] , while use of different penicillins may also affect prevalence of resistance to piperacillin/tazobactam in E. coli bacteremia [29] . Additionally, penicillins are widely prescribed in England, accounting for about half of all antibiotic prescriptions in primary care (e.g. Table 6 ), and penicillin use/resistance to penicillins is therefor expected to affect prevalence of infection/colonization with different bacterial pathogens that subsequently lead to bacteremia outcomes. While positive correlations between rates of bacteremia and rates of prescribing for penicillins other than amoxicillin/co-amoxiclav, but not for amoxicillin or coamoxiclav were found in this paper, it is uncertain which penicillins (including co-amoxiclav and amoxicillin) have a greater relative impact on rates of bacteremia, with the results of the correlation analyses in this paper potentially affected by patterns of prescribing of different antibiotics related to different geographic locations and demographic factors. Overall, our results support some replacement of penicillins in England by other antibiotics, presumably ones for which prevalence of antimicrobial resistance is lower, as well as reduction in penicillin prescribing with the aim of reducing bacteremia rates. Finally, we note that additional factors besides antibiotic choice affect the rates of severe infections associated with bacterial pathogens. Those factors include prevalence of underlying health conditions and certain demographic factors [34] . Additionally, we have found that prescribing of metronidazole for skin infections (BNF 1310012K0) as a proportion of the overall antibiotic prescribing is correlated with the CCG-specific rates of both E. coli and MSSA bacteremia per unit of antibiotic prescribing for the four years in the data. This suggests the possibility that demographic/geographic differences result in differences in transmission of infections/colonization with bacterial pathogens such as S. aureus and E. coli (including transmission through skin infections), which in turn may affect the rates of severe bacterial infections, including bacteremia.
Further work is needed to better understand those differences in transmission, including the feasibility of mitigation efforts aimed at preventing infections.
Our paper has some limitations. Associations between proportions of different antibiotic types/classes (particularly penicillins) and rates of severe outcomes associated with bacterial infections may be affected not only by the relative contributions of the use of a unit of different antibiotics to the rates of those severe outcomes but also by patterns of antibiotic prescribing in different locations. We note that penicillins are prescribed for a wide variety of indications, both in England and the US, affecting prevalence of infection/colonization with different bacterial pathogens, and that there is high prevalence of resistance to penicillins in both the Gram-negative and Gram-positive bacteria in the US (e.g. [31] [32] [33] ), and high prevalence of co-amoxiclav resistance in E. coli bacteremia in England [29] . The antibiotic-septicemia mortality associations we find in the multivariable model estimate causal effects only if the model is well-specified and all confounders are accounted for in the analysis. To adjust for potential effects of unmeasured and residual confounding, we included random effects for the ten US Health and Human Services regions, which led to an improvement in the model fits. Moreover, results of the univariate and the multivariable analyses generally agree on the direction of the effect of different antibiotics on the rates of mortality with septicemia (Tables 3 and 4) . Further work involving more granular data is needed to better ascertain the strength of the associations found in this paper. No hospital antibiotic prescribing data were available for this study, and in-hospital antibiotic prescribing is expected to have a significant impact on the rates of outcomes associated with severe bacterial infections. For example, given the very high prevalence of co-amoxiclav resistance in E. coli bacteremia and the high levels of co-amoxiclav prescribing outside the primary care setting in England [29, 50] , it is likely that co-amoxiclav prescribing in secondary care has a significant effect on the incidence of E. coli bacteremia, both co-amoxiclav resistant and overall. Coding practices for septicemia on death certificates may vary by US state [56] . Additionally, data on outpatient antibiotic prescribing in the whole population [35] were related to age-specific rates of mortality with septicemia in the US [36] , while in England, no age-specific prescribing or bacteremia data were available for this study. We expect that those sources of noise/incompatibility should generally reduce precision and bias the correlations towards null rather than create spurious associations.
We believe that despite those limitations, our results suggest that prescribing of certain antibiotics, particularly penicillins is associated with rates of E. coli and MSSA bacteremia in England and rates of mortality with septicemia in older US adults, with the latter result supporting our earlier findings about the association between the rates of prescribing of penicillins and rates of hospitalization and mortality with septicemia in older US adults [13, 14] . Additionally, there is high prevalence of resistance to penicillins for a variety of bacterial infections both in the US and England [31] [32] [33] 29, 50] . Further studies are needed to better understand the effect of replacement of certain antibiotics, particularly penicillins by others, well as of reduction in antibiotic prescribing in the treatment of certain syndromes on the rates of bacteremia, septicemia/sepsis and associated mortality.
